Mallinckrodt filed for bankruptcy protection, saddled with lawsuits alleging the company helped fuel the U.S. opioid epidemic.
After a disappointing end to a nine-year trial, the U.S. Food and Drug Administration officially gave AMAG Pharmaceuticals notice of the proposal to withdraw approval of Makena, an injectable progestin treatment to reduce preterm births.
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.
A federal appeals court threw out an order requiring AbbVie Inc. and a partner to disgorge $448 million in profit for trying to keep generic versions of the blockbuster testosterone replacement drug AndroGel off the market.
The U.S. Justice Department charged Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs.
A federal court upheld patent claims regarding Bristol Myers Squibb and Pfizer’s Eliquis, which blocks generic rivals from carving out a share of the market for at least six years.
Vanessa Brill, Vice President and Regional General Counsel for Dr. Reddy’s Laboratories operations in the Americas, discusses various topics including what she looks for in outside legal counsels and drug supply chain issues.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
The U.S. Justice Department charged Glenmark Pharmaceuticals with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
A federal appeals court upheld two patents for Amgen’s multibillion-dollar rheumatoid arthritis drug Enbrel, rejecting Novartis’ effort to void the patents.